作者: Wasaburo Koizumi , Isao Okayasu , Ichinosuke Hyodo , Junichi Sakamoto , Hiroshi Kojima
DOI: 10.1097/CAD.0B013E3283094B5D
关键词: Capecitabine 、 Performance status 、 Dihydropyrimidine dehydrogenase 、 Exact test 、 Gastroenterology 、 Cancer 、 Thymidine phosphorylase 、 Endocrinology 、 Chemotherapy 、 Immunohistochemistry 、 Internal medicine 、 Medicine
摘要: Abstract The objective of this study was to investigate the relationship between expression thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) response capecitabine in patients with advanced/recurrent gastric cancer. TP DPD paraffin-embedded specimens primary lesions, obtained from 25 before chemotherapy, were evaluated by immunohistochemical staining anti-TP anti-DPD monoclonal antibodies. (19 male six female) had a median age 65 years (range 37-74). All good performance status [Eastern Cooperative Oncology Group (ECOG) 0 or 1]. Overall rate therapy 32%. positive 19 tumors (76%) 13 (52%). (RR) significantly higher (Fisher's exact test, P=0.028) TP-positive DPD-negative (RR=60%, 6/10) than remaining (RR=13%, 2/15). profiles are useful for predicting capecitabine.